Loading...
950 logo

Lee's Pharmaceutical Holdings LimitedSEHK:950 Stock Report

Market Cap HK$1.5b
Share Price
HK$2.51
My Fair Value
HK$60.64
95.9% undervalued intrinsic discount
1Y112.7%
7D24.3%
Portfolio Value
View

Lee's Pharmaceutical Holdings Limited

SEHK:950 Stock Report

Market Cap: HK$1.5b

Lee's Pharmaceutical Holdings (950) Stock Overview

An investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. More details

950 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends2/6

950 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Lee's Pharmaceutical Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lee's Pharmaceutical Holdings
Historical stock prices
Current Share PriceHK$2.51
52 Week HighHK$2.70
52 Week LowHK$1.12
Beta0.63
1 Month Change26.77%
3 Month Change76.76%
1 Year Change112.71%
3 Year Change38.67%
5 Year Change-50.49%
Change since IPO382.69%

Recent News & Updates

We Think Lee's Pharmaceutical Holdings' (HKG:950) Profit Is Only A Baseline For What They Can Achieve

Sep 03
We Think Lee's Pharmaceutical Holdings' (HKG:950) Profit Is Only A Baseline For What They Can Achieve

Lee's Pharmaceutical Holdings (HKG:950) Is Due To Pay A Dividend Of HK$0.022

Aug 28
Lee's Pharmaceutical Holdings (HKG:950) Is Due To Pay A Dividend Of HK$0.022

Recent updates

We Think Lee's Pharmaceutical Holdings' (HKG:950) Profit Is Only A Baseline For What They Can Achieve

Sep 03
We Think Lee's Pharmaceutical Holdings' (HKG:950) Profit Is Only A Baseline For What They Can Achieve

Lee's Pharmaceutical Holdings (HKG:950) Is Due To Pay A Dividend Of HK$0.022

Aug 28
Lee's Pharmaceutical Holdings (HKG:950) Is Due To Pay A Dividend Of HK$0.022

Lee's Pharmaceutical Holdings Limited's (HKG:950) 26% Share Price Surge Not Quite Adding Up

Jul 30
Lee's Pharmaceutical Holdings Limited's (HKG:950) 26% Share Price Surge Not Quite Adding Up

Lee's Pharmaceutical Holdings (HKG:950) Will Pay A Larger Dividend Than Last Year At HK$0.025

Mar 31
Lee's Pharmaceutical Holdings (HKG:950) Will Pay A Larger Dividend Than Last Year At HK$0.025

What Lee's Pharmaceutical Holdings Limited's (HKG:950) P/E Is Not Telling You

Mar 20
What Lee's Pharmaceutical Holdings Limited's (HKG:950) P/E Is Not Telling You

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04
Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07
There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21
Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20
Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

May 21
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Apr 02
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Aug 29
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Apr 05
Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Shareholder Returns

950HK PharmaceuticalsHK Market
7D24.3%-4.7%0.9%
1Y112.7%81.5%51.1%

Return vs Industry: 950 exceeded the Hong Kong Pharmaceuticals industry which returned 81.5% over the past year.

Return vs Market: 950 exceeded the Hong Kong Market which returned 51.1% over the past year.

Price Volatility

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement13.3%
Pharmaceuticals Industry Average Movement6.5%
Market Average Movement7.3%
10% most volatile stocks in HK Market15.7%
10% least volatile stocks in HK Market3.5%

Stable Share Price: 950's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
19941,022n/awww.leespharm.com

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments.

Lee's Pharmaceutical Holdings Limited Fundamentals Summary

How do Lee's Pharmaceutical Holdings's earnings and revenue compare to its market cap?
950 fundamental statistics
Market capHK$1.48b
Earnings (TTM)HK$97.81m
Revenue (TTM)HK$1.44b
15.1x
P/E Ratio
1.0x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
950 income statement (TTM)
RevenueHK$1.44b
Cost of RevenueHK$673.63m
Gross ProfitHK$762.81m
Other ExpensesHK$665.01m
EarningsHK$97.81m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.17
Gross Margin53.10%
Net Profit Margin6.81%
Debt/Equity Ratio12.6%

How did 950 perform over the long term?

See historical performance and comparison

Dividends

2.0%
Current Dividend Yield
28%
Payout Ratio

Does 950 pay a reliable dividends?

See 950 dividend history and benchmarks
When do you need to buy 950 by to receive an upcoming dividend?
Lee's Pharmaceutical Holdings dividend dates
Ex Dividend DateSep 12 2025
Dividend Pay DateOct 03 2025
Days until Ex dividend7 days
Days until Dividend pay date14 days

Does 950 pay a reliable dividends?

See 950 dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/18 16:59
End of Day Share Price 2025/09/18 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lee's Pharmaceutical Holdings Limited is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Cheng3V Capital Limited
Yue-Kwong LuiBOCOM International Securities Limited
Chu WangCitigroup Inc